Bioventus Inc. Class A (BVS)
NASDAQ: BVSHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BVS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $676.53M
- P/E (TTM)
- 12.20
- Forward P/E
- 11.13
- EPS (TTM)
- $0.81
- Dividend yield
- None
- 52-week range
- 7.02 – 15.89
- Day range
- 9.81 – 10.17
- Volume / Avg
- 612.43K / 536.81K
- Beta
- —
- Shares outstanding
- 68.47M
52-week range
BVS stock today
Shares of Bioventus (BVS) finished lower on Nov 20 at $9.88, a drop of 0.70% or $0.07 per share, versus the S&P 500's 3.70% decline. Shares are 37.8% below their 52-week high of $15.89, set on Aug 5, 2026 and 40.8% above the 52-week low of $7.02, in the middle of the past year's range. BVS is up 32.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 36.5%.
Bioventus trades at 12.2x its trailing twelve-month earnings per share of $0.81. Its forward P/E of 11.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Bioventus
Company profileBioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Robert E. Claypoole
- Headquarters
- Durham, NC
- Employees
- 960
- IPO year
- 2021
- Website
- bioventus.com
Financial highlights
Full financialsIn fiscal 2025, Bioventus generated $568.1 million in revenue, down 0.9% from fiscal 2024, its first annual decline since 2020. Net income was $22.7 million, for a net margin of 4.0% versus a median of -6.3% in the prior 5 years. Gross margin was 68.3% (up from 67.7%) and operating margin 9.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $568.09M | $573.28M | $512.35M | $512.12M | $430.90M |
| Growth | -0.91% | +11.89% | +0.04% | +18.85% | +34.17% |
| Net income | $22.73M | $-36.13M | $-156.23M | $-158.70M | $19.38M |
| EPS (diluted) | $0.33 | $-0.56 | $-2.49 | $-2.59 | $-0.15 |
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$16.60+68.02%
- Strong buy 2
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 2, 2026
- EPS actual vs est.
- $0.08 vs $0.17
- Surprise
- -52.94%
BVS news
All BVS news- Bioventus Reports Higher Q3 Profit, Cuts 2026 Sales Outlook; Stock DownNasdaqBVS, UHAL.B
- Bioventus expects 2026 revenue of $590M-$595M while reaffirming adjusted EPS of $0.75-$0.79Seeking Alpha
- Bioventus (BVS) Q3 2026 Earnings Call TranscriptNasdaq
- Bioventus Non-GAAP EPS of $0.17 beats by $0.01, revenue of $142.4M misses by $7.12MSeeking Alpha
- Bioventus Reports Third Quarter Financial ResultsGlobeNewswire
- Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026GlobeNewswire
Bioventus peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DCTHDelcath Systems Inc. | 18.79 | -2.34% | $653.67M | vs BVS |
| BBNXBeta Bionics Inc. | 13.36 | +0.30% | $726.34M | vs BVS |
| VVVVvVARDIS Holding AG Class A | 14.55 | -3.00% | $770.91M | vs BVS |
| TCMDTactile Systems Technology Inc. | 25.60 | -1.50% | $573.48M | vs BVS |
| SGHTSight Sciences Inc. | 10.18 | -4.14% | $565.79M | vs BVS |
| KIDSOrthoPediatrics Corp. | 31.74 | -2.37% | $828.75M | vs BVS |
| RCELAvita Medical Inc. | 15.62 | -2.31% | $494.96M | vs BVS |
| CARLCarlsmed Inc. | 17.42 | +1.16% | $477.38M | vs BVS |
Indexes, lists and sector
Bioventus stock FAQ
What is Bioventus's stock price today?
BVS last traded at $9.88 as of Nov 20, 4:00 PM EST, down 0.70% on the day. Prices are delayed at least 15 minutes.
What is BVS's P/E ratio?
BVS trades at a trailing P/E ratio of 12.20 and a forward P/E of 11.13.
Who is Bioventus's CEO?
Mr. Robert E. Claypoole is the chief executive officer of Bioventus Inc. Class A, which has about 960 employees.
What is the BVS 52-week high?
The 52-week high for BVS is $15.89 and the 52-week low is $7.02. The stock is currently 37.8% below its high.